Home › Funds › ACORN CAPITAL ADVISORS, LLC › PBYI

ACORN CAPITAL ADVISORS, LLC position in PBYI

PUMA BIOTECHNOLOGY INC · Health Care

ACORN CAPITAL ADVISORS, LLC reported holding 4,131,299 shares of PBYI (PUMA BIOTECHNOLOGY INC) in its Q3 2026 13F filing — a position valued at US$41.0M, representing 11.27% of its reported portfolio and ranking #3 among its reported holdings. ACORN CAPITAL ADVISORS, LLC has disclosed PBYI holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)4.13M sh
Reported value held$41.02M
Portfolio Weight11.27%
First reportedQ4 2024
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ACORN CAPITAL ADVISORS, LLC's PBYI position evolved

ACORN CAPITAL ADVISORS, LLC first disclosed a stake in PBYI in Q4 2024 at 3,940,052 shares (US$12.0M). The position peaked in Q3 2026 at 4,131,299 shares, worth US$41.0M. Across 8 filings, ACORN CAPITAL ADVISORS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 4,131,299 shares valued at US$41.0M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 3.94M $12.02M New
Q1 2025 3.94M $11.66M Hold
Q2 2025 4.13M $14.17M Add
Q3 2025 4.13M $21.94M Hold
Q4 2025 4.13M $24.58M Hold
Q1 2026 4.13M $26.40M Hold
Q2 2026 4.13M $33.50M Hold
Q3 2026 4.13M $41.02M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PBYI and 13F data

PBYI (PUMA BIOTECHNOLOGY INC) is a Health Care company. 40 other funds we track also report a position in PBYI. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PBYI

No other tracked fund reports a position in PBYI.

All PBYI fund holders →

FAQ

How long has ACORN CAPITAL ADVISORS, LLC held PBYI?

ACORN CAPITAL ADVISORS, LLC has disclosed PBYI holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is ACORN CAPITAL ADVISORS, LLC's current position in PBYI?

As of Q3 2026, ACORN CAPITAL ADVISORS, LLC holds 4.13M shares of PBYI (PUMA BIOTECHNOLOGY INC), valued at $41.02M, representing 11.27% of its reported portfolio and ranking #3.

Has ACORN CAPITAL ADVISORS, LLC been buying or selling PBYI?

In the latest 13F filing (Q3 2026), ACORN CAPITAL ADVISORS, LLC held unchanged its position in PBYI. The position peaked in Q3 2026 at 4.13M shares.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.